InterMune Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

ITMN 0.0000
price chart
InterMune CEO: Bittersweet ending to biotech's comeback story
InterMune Inc.'s comeback story - from a drug rejection by the FDA to an $8.3 billion buyout offer Sunday from drug giant Roche - is mixed for Dan Welch.
Roche to buy US biotech firm InterMune for $8.3 billion  Reuters UK
InterMune Inc. Shareholders Can Now Breathe Easier Thanks to Roche  Motley Fool
Related articles »  
InterMune to Divest Actimmune� (Interferon Gamma-1b)
BRISBANE, Calif., May 21, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune� (interferon gamma-1b) in a ...
InterMune Is Set To Outperform Its Main Competitor
InterMune's (ITMN) sole product pirfenidone (brand name Esbriet) is an orally active, small molecule drug currently seeking approval from the FDA for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease.
InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal
A treatment for a fatal lung-scarring disease - the center of an $8.3 billion buyout of a Peninsula company by drug giant Roche - won regulatory approval Wednesday.
InterMune drug may offer big upside to Roche if aimed at liver
(Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its ...
New Merger Bolsters Development of Drug For Idiopathic Pulmonary Fibrosis, a ...  Pulmonary Hypertension News
Related articles »  
InterMune Announces Senior Leadership Appointments to Prepare for Launch of ...
BRISBANE, Calif., Dec. 17, 2010 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe.
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
InterMune reported Esbriet� (pirfenidone) revenue in the second quarter of 2014 of $35.7 million, compared with $14.4 million in the second quarter of 2013, an increase of 148 percent.
Related articles »  
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic ...
BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone ...
InterMune Lung Drug Is Successful in New Trial  New York Times
Related articles »  
4 winners, 3 losers in Roche's $8.3 billion takeover of InterMune
“Company B,” the company in an InterMune SEC filing whose CEO was scheduled to talk to InterMune's Welch but cancelled.
Related articles »  
Ex-InterMune Director Barred From Boards For Insider Trading
Law360, New York (May 16, 2017, 8:18 PM EDT) -- A California federal magistrate judge on Monday permanently barred a former InterMune Inc. director from serving as an officer or director in a publicly traded company and refused to toss a jury verdict ...